XTuit Believes Microenvironment Approach Will Yield Cancer And Fibrosis Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Coming out of stealth with a $22 million Series A round, the biotech thinks its therapies targeting abnormal stroma could improve the activity of checkpoint inhibitors in cancer combo therapy and possibly reverse fibrosis in advanced liver disease.
You may also be interested in...
Dunsire Takes XTuit Helm As First Targets Approach The Clinic
The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.